Cargando…
Modeling buprenorphine reduction of fentanyl-induced respiratory depression
BACKGROUND: Potent synthetic opioids, such as fentanyl, are increasingly abused, resulting in unprecedented numbers of fatalities from respiratory depression. Treatment with the high-affinity mu-opioid receptor partial agonist buprenorphine may prevent fatalities by reducing binding of potent opioid...
Autores principales: | Olofsen, Erik, Algera, Marijke Hyke, Moss, Laurence, Dobbins, Robert L., Groeneveld, Geert J., van Velzen, Monique, Niesters, Marieke, Dahan, Albert, Laffont, Celine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090248/ https://www.ncbi.nlm.nih.gov/pubmed/35316224 http://dx.doi.org/10.1172/jci.insight.156973 |
Ejemplares similares
-
Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients
por: Moss, Laurence M., et al.
Publicado: (2022) -
Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve Individuals
por: Algera, Marijke Hyke, et al.
Publicado: (2020) -
A biomarker of opioid-induced respiratory toxicity in experimental studies
por: Hellinga, Marieke, et al.
Publicado: (2023) -
Pharmacokinetic–Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats
por: Yassen, Ashraf, et al.
Publicado: (2007) -
Are thyrotropin‐releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid‐induced respiratory depression?
por: Algera, Marieke Hyke, et al.
Publicado: (2022)